View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 23, 2022

Lung Therapeutics concludes Phase Ia trial of IPF asset

Dose levels ranging from 2.5mg to 10mg of LTI-03 were demonstrated to be safe and well-tolerated.

Lung Therapeutics has concluded the Phase Ia clinical trial of its Caveolin-1-related peptide, LTI-03, intended for the treatment of idiopathic pulmonary fibrosis (IPF).

A seven amino acid peptide, LTI-03, addresses hindrance of pro-fibrotic signalling and key epithelial cell survival.

The company noted that LTI-03 is a dry powder formulation intended for direct-to-lung administration.

The trial evaluated ascending doses of LTI-03 in healthy subjects. 

According to the findings from the trial, dose levels ranging from 2.5mg to 10mg of LTI-03 were demonstrated to be safe and well-tolerated.

Furthermore, no study discontinuations or serious adverse events were reported in this trial. 

Lung Therapeutics president and CEO Brian Windsor said: “We are pleased that LTI-03 has passed this important safety milestone as we continue development. 

“We believe that the mechanism LTI-03 is unique among drugs in development for IPF, and we are excited to move LTI-03 into the next stage of clinical development in IPF patients later this year.”

The company noted that LTI-03 performed well at dose levels equivalent to a human dose ranging from 1 to 10mg in preclinical animal and ex-vivo models.

In addition, these preclinical data showed that the treatment with LTI-03 hindered pro-fibrotic signalling and preserved critical alveolar epithelial type 2 (AEC2) cells in the lungs.

Lung Therapeutics and Taiho Pharmaceutical signed an exclusive license agreement in November 2020 for a recombinant human single-chain urokinase plasminogen activator, LTI-01, in Japan.

In March 2017, the company commenced subject enrolment and dosing in a Phase Ia/b trial of LTI-01 to treat patients with loculated pleural effusions in Australia and New Zealand.

Related Companies

Free Whitepaper

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy